Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics, siRNA platforms, gene therapy, and other genetic medicine approaches for rare diseases. The company’s marketed Duchenne muscular dystrophy products include EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, the latter being an AAV-based gene therapy. Sarepta is also advancing several development programs, including SRP-9003 for LGMD2E and early-stage candidates SRP-1001 and SRP-1003. In addition, it has collaboration and license agreements with F. Hoffman-La Roche Ltd, Arrowhead Pharmaceuticals, the University of Western Australia, Nationwide Children’s Hospital, Hansa Biopharma, and Duke University. Sarepta Therapeutics was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SRPT
|
$20.39
|
20.9% Upside
|
Undervalued
|
$22.17
|
31.4% Upside
|
Undervalued
|
Good
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
27.3x
|
1.2x
|
0.8x
|
1.777 B
|
2.082 B
|
37.1%
|
89.6%
|
0.0
|
—
|
176.6%
|
